MaxCyte Inc. Common Stock (MXCT)

FairStock Score: 46/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett-style investor, I want a durable business, honest earnings, and a margin of safety. MaxCyte is a small life-sciences toolmaker with 91 employees, selling electroporation instruments. The numbers are not yet those of a healthy business. In fiscal 2025, the year ended 2025-12-31, revenue was $21.0 million, down from $22.2 million in fiscal 2024. The net loss widened to $44.6 million from $41.1 million. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $4.9 million and net loss was $8.9 million; the loss improved from fiscal Q2 2025's $12.4 million, but revenue also slipped from $5.8 million. Trailing free cash flow is -$23.8 million, a -23.9% FCF yield on the $99.5 million market cap, so the company is consuming cash. The balance sheet has low debt, with D/E of 0.11, but FairStock's Altman Z-score of 0.80 and Piotroski F-score of 3/9 point to fragility. At the 2026-10-13 close of $0.96, FairStock's P/B is 0.64, which is the main attraction. Yet P/E is -2.84 and ROE is -20.39%, showing no earnings power. The Lynch category is none because the company lost money in each of the last four years. Without evidence of a durable moat or a path to positive cash flow, this looks like a speculative asset play, not a compounding machine. I would need a far wider discount before calling it a Graham-style bargain.

In plain English: MaxCyte makes tools that help modify cells for medical research and treatment. The business is not yet profitable, sales have been falling recently, and it burns cash. At $0.96, the stock looks cheap compared with its accounting net assets, but the weak losses make it risky and not clearly a bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer